The state of Massachusetts currently has 532 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Pilot of 18F-DCFPyL-PSMA PET in MCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Recruiting
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Recruiting
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: Brigham & Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Microdevice in Ovarian, Fallopian Tube, and Peritoneal Cancer
Recruiting
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implantable microdevice
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Recruiting
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might he... Read More
Gender:
MALE
Ages:
Between 55 years and 69 years
Trial Updated:
01/29/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Prostate Cancer
PRISM for Depression and Anxiety in Young Adults with Cancer
Recruiting
This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
01/29/2025
Locations: Dana-Farber Cancer Institute, Brighton, Massachusetts
Conditions: Cancer Diagnosis, Non-Metastatic Neoplasm, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Depression, Anxiety, Desmoid
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Urothelial Carcinoma, Bladder Cancer
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Recruiting
This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma
Intervention For AYAS With Cancer Risk Syndromes
Recruiting
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of dev... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
01/28/2025
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Cancer Risk Syndrome
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
Recruiting
The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensities among individuals with advanced lung cancer receiving immune checkpoint inhibitors. The names of the study interventions involved in this study are:
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lung Cancer
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Recruiting
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Recruiting
This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Docetaxel and cyclophosphamide are commonly used, but is not well tolerated at the... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Massachusetts General Hospital - Dana Farber, Boston, Massachusetts
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer